2024-10-16 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational pharmaceutical, medical device, and consumer packaged goods company. Its cumulative return is **34.75%**, lagging behind the S&P 500 (VOO) with a cumulative return of **135.82%**. This translates to a **-101.07%** performance gap, placing it at the **3.93%** percentile of historical performance relative to the S&P 500. 

**2. Recent Price Movement:**

* **Closing Price:** $161.46
* **5-Day Moving Average:** $160.36
* **20-Day Moving Average:** $162.36
* **60-Day Moving Average:** $161.75

JNJ's price is currently trading slightly below its 20-day and 60-day moving averages, indicating a possible short-term downward trend.

**3. Technical Indicators:**

* **RSI:** 41.54 - This suggests JNJ is currently in a neutral zone, neither overbought nor oversold.
* **PPO:** -0.15 - This indicates a potential short-term bearish trend. 
* **Delta_Previous_Relative_Divergence:** -8.37 - This indicates a short-term downward trend in relative performance against the S&P 500.
* **Expected Return:** 0.0% - This indicates a potential 5-year expected return of 0% over the S&P 500 (VOO).

**4. Recent Earnings and Outlook:**

| Date       | EPS     | Revenue        |
|------------|---------|-----------------|
| 2024-07-25 | 1.95    | 22.45 B$        |
| 2024-05-01 | 1.35    | 21.38 B$        |
| 2024-02-16 | 1.68    | 21.39 B$        |
| 2023-10-27 | 10.32   | 21.35 B$        |
| 2024-02-16 | 10.32   | 21.35 B$        |

JNJ's most recent earnings report, for Q2 2024, showed a 1.95 EPS against an analyst estimate of 2.01.  This signifies a minor miss in expectations, which could be contributing to the current downward pressure on the stock price. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** JNJ's stock performance has been influenced by factors such as the ongoing legal battles related to its talcum powder products and the overall slowdown in the pharmaceutical industry. 
* **Analyst Opinions:** Analysts have expressed mixed sentiments about JNJ's future prospects. Some remain bullish citing its strong dividend history and diversified business model, while others are more cautious due to the legal concerns and competitive pressures in the industry. 
* **Performance Highlights:** JNJ's stock price has been volatile in recent months, but the company continues to demonstrate resilience through its consistent dividend payments and its focus on innovation. 

**6. Overall Analysis:**

Johnson & Johnson's recent underperformance compared to the S&P 500 is driven by a combination of factors, including legal issues, market headwinds, and the recent earnings miss. While its strong dividend history and diverse portfolio offer some comfort, the company's future performance will depend on its ability to resolve the ongoing legal challenges and maintain its competitive edge in a dynamic market.  Investors should closely monitor these developments and weigh them against their own risk tolerance and investment goals. 

**7. English Report:**

This report offers an overview of JNJ's current performance, recent price movements, technical indicators, and recent earnings. While the stock has experienced some downward pressure, its long-term value proposition remains strong, with factors such as its dividend payments and robust portfolio offering potential for investors.  However, investors should closely monitor the legal landscape and other factors impacting the company before making investment decisions. 
